© 2003 by Oxford University Press
© 2003 Oxford University Press
ARTICLE |
A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer
For the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group
Affiliations of authors: A. du Bois, Department of Gynecology and Gynecologic Oncology, Dr.-Horst-Schmidt-Kliniken, Wiesbaden, Germany, and Department of Gynecology and Obstetrics, St.-Vincentius-Hospital, Karlsruhe, Germany; H.-J. Lück, Department of Gynecologic Oncology, Medizinische Hochschule, Hannover, Germany; W. Meier, Department of Gynecology and Obstetrics, University München-Gro
hadern, Germany; H.-P. Adams, Methodisches Zentrum–GynDat, Dr.-Horst-Schmidt-Kliniken, Wiesbaden; V. Möbus, Department of Gynecology and Obstetrics, University of Ulm, Germany; S. Costa, Department of Gynecology and Obstetrics, University of Frankfurt, Germany; T. Bauknecht, Department of Gynecology and Obstetrics, University of Freiburg, Germany; B. Richter, Department of Gynecology and Obstetrics, University of Dresden, Germany; M. Warm, Department of Gynecology and Obstetrics Klinikum, Stralsund, Germany; W. Schröder, Department of Gynecology and Obstetrics, Rheinisch-Westfälische Technische Hochschule, Aachen, Germany; S. Olbricht, Department of Gynecology and Obstetrics, Medizinische Akademie, Magdeburg, Germany; U. Nitz, Department of Gynecology and Obstetrics, University of Düsseldorf, Germany; C. Jackisch, Department of Gynecology and Obstetrics, University of Münster, Germany; G. Emons, U. Wagner, Department of Gynecology, University of Marburg, Germany; W. Kuhn, Department of Gynecology and Obstetrics, University München rechts der Isar, Germany; J. Pfisterer, Department of Gynecology and Obstetrics, University Kiel, Germany.
Correspondence to: Andreas du Bois, MD, PhD, Dr.-Horst-Schmidt-Kliniken, Dept. of Gynecology and Gynecologic Oncology, Ludwig-Erhard-Str. 100, D-65199 Wiesbaden, Germany (e-mail: dubois.hsk-wiesbaden{at}uumail.de).
Background: Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue. Therefore, we performed a randomized, phase III non-inferiority trial comparing paclitaxel plus cisplatin (PT) with paclitaxel plus carboplatin (TC) in patients with advanced ovarian cancer. Methods: A total of 798 patients with International Federation of Gynecology and Obstetrics stage IIB–IV were randomly assigned to receive six courses of either PT or TC at 3-week intervals. The primary endpoint was the proportion of patients without progression at 2 years. Secondary endpoints included toxicity, response to treatment, quality of life, and overall and progression-free survival time. Quality of life was evaluated using the European Organization for Research and Treatment of Cancer quality-of-life questionnaire (QLQ)-C30, version 2.0. Survival curves were calculated using the Kaplan–Meier method, and hazard ratios were estimated using the Cox proportional hazards model. Results: The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = –
to 8.2%). Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different; the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively). The TC regimen was associated with a higher frequency of hematologic toxicity, but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen. Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = –13.28, 95% CI = –18.88 to –7.68). Conclusion: The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. E. Johnatty, J. Beesley, J. Paul, S. Fereday, A. B. Spurdle, P. M. Webb, K. Byth, S. Marsh, H. McLeod, AOCS Study Group, et al. ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy Clin. Cancer Res., September 1, 2008; 14(17): 5594 - 5601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Engels, S. K. Knauer, S. Loibl, V. Fetz, P. Harter, A. Schweitzer, A. Fisseler-Eckhoff, F. Kommoss, L. Hanker, V. Nekljudova, et al. NO Signaling Confers Cytoprotectivity through the Survivin Network in Ovarian Carcinomas Cancer Res., July 1, 2008; 68(13): 5159 - 5166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Fotopoulou, A. duBois, A. N. Karavas, R. Trappe, B. Aminossadati, B. Schmalfeldt, J. Pfisterer, and J. Sehouli Incidence of Venous Thromboembolism in Patients With Ovarian Cancer Undergoing Platinum/Paclitaxel-Containing First-Line Chemotherapy: An Exploratory Analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group J. Clin. Oncol., June 1, 2008; 26(16): 2683 - 2689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. C. Swart, S. Burdett, J. Ledermann, P. Mook, and M. K. B. Parmar Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review Ann. Onc., April 1, 2008; 19(4): 688 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Joerger, A. D.R. Huitema, D. J. Richel, C. Dittrich, N. Pavlidis, E. Briasoulis, J. B. Vermorken, E. Strocchi, A. Martoni, R. Sorio, et al. Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group Clin. Cancer Res., November 1, 2007; 13(21): 6410 - 6418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Marsh, J. Paul, C. R. King, G. Gifford, H. L. McLeod, and R. Brown Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer J. Clin. Oncol., October 10, 2007; 25(29): 4528 - 4535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Mobus, H. Wandt, N. Frickhofen, C. Bengala, K. Champion, R. Kimmig, H. Ostermann, A. Hinke, and J. A. Ledermann Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT J. Clin. Oncol., September 20, 2007; 25(27): 4187 - 4193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Trope and J. Kaern Adjuvant Chemotherapy for Early-Stage Ovarian Cancer: Review of the Literature J. Clin. Oncol., July 10, 2007; 25(20): 2909 - 2920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dorn, M. Schmitt, R. Kates, B. Schmalfeldt, M. Kiechle, A. Scorilas, E. P. Diamandis, and N. Harbeck Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients Clin. Cancer Res., March 15, 2007; 13(6): 1742 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Hilpert, A du Bois, E. Greimel, J Hedderich, G Krause, L Venhoff, S Loibl, and J Pfisterer Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany Ann. Onc., February 1, 2007; 18(2): 282 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O Tredan, J-F Geay, S Touzet, R Delva, B Weber, J Cretin, J Provencal, J Martin, L Stefani, E Pujade-Lauraine, et al. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens Ann. Onc., February 1, 2007; 18(2): 256 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kyrgiou, G. Salanti, N. Pavlidis, E. Paraskevaidis, and J. P. A. Ioannidis Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments. J Natl Cancer Inst, November 15, 2006; 98(22): 1655 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, A. J. Lacave, U. Wagner, A. Stahle, G. Stuart, R. Kimmig, et al. Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J. Clin. Oncol., October 10, 2006; 24(29): 4699 - 4707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gore, A. du Bois, and I. Vergote Intraperitoneal Chemotherapy in Ovarian Cancer Remains Experimental J. Clin. Oncol., October 1, 2006; 24(28): 4528 - 4530. [Full Text] [PDF]
|
|
|
|
|
|
J Pfisterer, A du Bois, J Sehouli, S Loibl, S Reinartz, A Reuss, U Canzler, A Belau, C Jackisch, R Kimmig, et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann. Onc., October 1, 2006; 17(10): 1568 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pfisterer, B. Weber, A. Reuss, R. Kimmig, A. du Bois, U. Wagner, H. Bourgeois, W. Meier, S. Costa, J.-U. Blohmer, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst, August 2, 2006; 98(15): 1036 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bhoola and W. J. Hoskins Diagnosis and management of epithelial ovarian cancer. Obstet. Gynecol., June 1, 2006; 107(6): 1399 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Viens, T. Petit, A. Yovine, P. Bougnoux, G. Deplanque, P.-H. Cottu, R. Delva, J.-P. Lotz, S. V. Belle, J.-M. Extra, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients Ann. Onc., March 1, 2006; 17(3): 429 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Markman and J. L. Walker Intraperitoneal Chemotherapy of Ovarian Cancer: A Review, With a Focus on Practical Aspects of Treatment J. Clin. Oncol., February 20, 2006; 24(6): 988 - 994. [Full Text] [PDF]
|
|
|
|
|
|
E. R. Greimel, V. Bjelic-Radisic, J. Pfisterer, F. Hilpert, F. Daghofer, and A. du Bois Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel J. Clin. Oncol., February 1, 2006; 24(4): 579 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Aravantinos, G. Fountzilas, P. Kosmidis, M. A. Dimopoulos, G. P. Stathopoulos, N. Pavlidis, D. Bafaloukos, C. Papadimitriou, S. Karpathios, V. Georgoulias, et al. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study Ann. Onc., July 1, 2005; 16(7): 1116 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Cannistra Cancer of the Ovary N. Engl. J. Med., December 9, 2004; 351(24): 2519 - 2529. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Vasey, G. C. Jayson, A. Gordon, H. Gabra, R. Coleman, R. Atkinson, D. Parkin, J. Paul, A. Hay, S. B. Kaye, et al. Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian Carcinoma J Natl Cancer Inst, November 17, 2004; 96(22): 1682 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bezjak, D. Tu, M. Bacon, D. Osoba, B. Zee, G. Stuart, J.-A. Roy, M. Piccart, and E. Eisenhauer Quality of Life in Ovarian Cancer Patients: Comparison of Paclitaxel Plus Cisplatin, With Cyclophosphamide Plus Cisplatin in a Randomized Study J. Clin. Oncol., November 15, 2004; 22(22): 4595 - 4603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. De Placido, G. Scambia, G. Di Vagno, E. Naglieri, A. V. Lombardi, R. Biamonte, M. Marinaccio, G. Carteni, L. Manzione, A. Febbraro, et al. Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study J. Clin. Oncol., July 1, 2004; 22(13): 2635 - 2642. [Abstract] [Full Text] [PDF]
|
|